Replimune Group Financials
This page shows Replimune Group (REPL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Escalating research investment produces cash-heavy losses while Replimune’s balance sheet shifts toward greater debt financing.
In FY2026, net loss was-$313.9M versus operating cash flow of-$280.3M , indicating that accounting losses were closely mirrored by cash consumption rather than being mainly noncash. Free cash flow of-$284.6M reinforces the same weak cash conversion pattern.
R&D climbed from
Debt-to-equity rose from 0.1x in FY2024 to 0.5x in FY2026 while the current ratio fell from 8.0x to 4.8x, showing a less equity-dominant and less liquid balance-sheet posture. Equity also declined from
Financial Health Signals
Replimune Group does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Replimune Group passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Replimune Group reported a net loss of $313.9M while operations used $280.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Replimune Group reported an operating loss of $319.9M against $6.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Replimune Group's EBITDA was -$316.6M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 22.6% from the prior year.
Replimune Group reported -$313.9M in net income in fiscal year 2026. This represents a decrease of 26.9% from the prior year.
Replimune Group earned -$3.38 per diluted share (EPS) in fiscal year 2026. This represents a decrease of 10.1% from the prior year.
Not reported for fiscal year 2026.
Cash & Balance Sheet
Replimune Group recorded an outflow of $284.6M in free cash flow in fiscal year 2026, representing a cash shortfall after capex. This represents a decrease of 43.0% from the prior year.
Replimune Group held $209.0M in cash against $83.3M in long-term debt as of fiscal year 2026.
Not reported for fiscal year 2026.
Margins & Returns
Replimune Group's ROE was -188.9% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 129.4 percentage points from the prior year.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Capital Allocation
Replimune Group invested $221.2M in research and development in fiscal year 2026. This represents an increase of 16.8% from the prior year.
Replimune Group invested $4.2M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 36.8% from the prior year.
Not reported for fiscal year 2026.
REPL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $49.3M | N/A | $53.1M-8.2% | $57.9M+0.1% | $57.8M | N/A | $48.0M+10.5% | $43.4M |
| SG&A Expenses | $19.0M | N/A | $18.7M-29.1% | $26.4M-18.9% | $32.6M | N/A | $18.0M+16.5% | $15.5M |
| Operating Income | -$68.2M | N/A | -$71.9M+14.7% | -$84.3M+6.8% | -$90.4M | N/A | -$66.0M-12.1% | -$58.9M |
| Interest Expense | $2.6M | N/A | $1.5M-1.5% | $1.5M+0.9% | $1.5M | N/A | $1.4M+0.8% | $1.4M |
| Income Tax | N/A | N/A | -$311K | $0 | $0 | N/A | $575K | $0 |
| Net Income | -$69.8M | N/A | -$70.9M+14.6% | -$83.1M+4.1% | -$86.7M | N/A | -$66.3M-25.0% | -$53.1M |
| EPS (Diluted) | -$0.72+5.3% | -$0.76+1.3% | -$0.77+14.4% | -$0.90+5.3% | -$0.95-15.9% | -$0.82-3.8% | -$0.79-16.2% | -$0.68 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
REPL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $252.4M-24.1% | $332.4M-0.4% | $333.6M-14.3% | $389.4M-17.1% | $469.5M-14.8% | $551.3M-8.7% | $603.6M+21.2% | $498.2M |
| Current Assets | $200.8M-28.1% | $279.1M-0.4% | $280.4M-16.0% | $333.7M-19.3% | $413.4M-16.6% | $495.9M-9.4% | $547.6M+23.7% | $442.6M |
| Cash & Equivalents | $185.4M-11.3% | $209.0M+70.0% | $123.0M+20.2% | $102.3M+5.1% | $97.4M-12.4% | $111.1M-35.5% | $172.2M+51.8% | $113.5M |
| Total Liabilities | $146.8M-11.7% | $166.2M+35.1% | $123.1M-2.4% | $126.1M-5.0% | $132.8M-2.0% | $135.5M+11.7% | $121.3M+3.9% | $116.7M |
| Current Liabilities | $38.4M-34.0% | $58.2M+16.3% | $50.1M-5.3% | $52.9M-11.2% | $59.6M-4.5% | $62.4M+30.2% | $47.9M+9.4% | $43.8M |
| Long-Term Debt | $84.1M+1.0% | $83.3M+74.9% | $47.6M+0.9% | $47.2M+0.9% | $46.8M+0.9% | $46.4M+0.9% | $46.0M+0.9% | $45.6M |
| Total Equity | $105.6M-36.4% | $166.2M-21.1% | $210.5M-20.0% | $263.3M-21.8% | $336.7M-19.0% | $415.8M-13.8% | $482.4M+26.5% | $381.5M |
| Retained Earnings | -$1.3B-5.5% | -$1.3B-6.2% | -$1.2B-6.3% | -$1.1B-8.0% | -$1.0B-9.1% | -$948.6M-8.5% | -$874.4M-8.2% | -$808.1M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
REPL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$75.7M-34.8% | -$56.2M+14.8% | -$66.0M+18.8% | -$81.2M-5.4% | -$77.0M-43.3% | -$53.7M-6.0% | -$50.7M-31.2% | -$38.6M |
| Capital Expenditures | $6K+20.0% | $5K-96.3% | $135K-89.9% | $1.3M-51.0% | $2.7M+141.6% | $1.1M-37.0% | $1.8M-13.6% | $2.1M |
| Free Cash Flow | -$75.7M-34.8% | -$56.2M+15.0% | -$66.1M+19.9% | -$82.6M-3.5% | -$79.8M-45.4% | -$54.9M-4.5% | -$52.5M-29.0% | -$40.7M |
| Investing Cash Flow | $50.0M-42.2% | $86.5M+15.2% | $75.1M-10.8% | $84.2M+29.4% | $65.0M+944.8% | -$7.7M+83.4% | -$46.3M-10213.5% | $458K |
| Financing Cash Flow | $800K-98.6% | $55.7M+432.7% | $10.5M+3125.6% | $324K+305.1% | -$158K-19.7% | -$132K-100.1% | $155.9M+399920.5% | -$39K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
REPL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -66.0% | N/A | -33.7%-2.1pp | -31.6%-5.8pp | -25.8% | N/A | -13.8%+0.2pp | -13.9% |
| Return on Assets | -27.6% | N/A | -21.3%+0.1pp | -21.3%-2.9pp | -18.5% | N/A | -11.0%-0.3pp | -10.7% |
| Current Ratio | 5.23+0.4x | 4.79-0.8x | 5.60-0.7x | 6.31-0.6x | 6.94-1.0x | 7.95-3.5x | 11.43+1.3x | 10.11 |
| Debt-to-Equity | 0.80+0.3x | 0.50+0.3x | 0.230.0x | 0.180.0x | 0.140.0x | 0.110.0x | 0.100.0x | 0.12 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Replimune Group Ranks
Frequently Asked Questions
Is Replimune Group profitable?
No, Replimune Group (REPL) reported a net income of -$313.9M in fiscal year 2026.
What is Replimune Group's EBITDA?
Replimune Group (REPL) had EBITDA of -$316.6M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Replimune Group have?
As of fiscal year 2026, Replimune Group (REPL) had $209.0M in cash and equivalents against $83.3M in long-term debt.
What is Replimune Group's return on equity (ROE)?
Replimune Group (REPL) has a return on equity of -188.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Replimune Group's free cash flow?
Replimune Group (REPL) recorded an outflow of $284.6M in free cash flow during fiscal year 2026. This represents a -43.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Replimune Group's operating cash flow?
Replimune Group (REPL) recorded an outflow of $280.3M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Replimune Group's total assets?
Replimune Group (REPL) had $332.4M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Replimune Group's capital expenditures?
Replimune Group (REPL) invested $4.2M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Replimune Group spend on research and development?
Replimune Group (REPL) invested $221.2M in research and development during fiscal year 2026.
What is Replimune Group's current ratio?
Replimune Group (REPL) had a current ratio of 4.79 as of fiscal year 2026, which is generally considered healthy.
What is Replimune Group's debt-to-equity ratio?
Replimune Group (REPL) had a debt-to-equity ratio of 0.50 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Replimune Group's return on assets (ROA)?
Replimune Group (REPL) had a return on assets of -94.4% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
How does Replimune Group's liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Replimune Group (REPL) held $268.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $280.3M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Replimune Group's Piotroski F-Score?
Replimune Group (REPL) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Replimune Group's earnings high quality?
Replimune Group (REPL) reported a net loss of $313.9M while operations used $280.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Replimune Group cover its interest payments?
Replimune Group (REPL) reported an operating loss of $319.9M against $6.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.